MannKind Discontinues Phase 3 Trial of Nebulized Clofazimine to Treat Lung Disease
MT Newswires Live
Nov 10, 2025
MannKind (MNKD) said Monday it has discontinued its phase 3 trial evaluating MNKD-101, a nebulized clofazimine inhalation suspension, for the treatment of nontuberculous mycobacterial lung disease.
The company said no sputum culture conversions were observed from the first 46 participants who completed the double-blind treatment phase and the Data Safety Monitoring Board agreed with the decision to discontinue the trial due to futility.
MannKind said the the outcome does not affect plans for MNKD-102, its dry powder inhalation clofazimine, which remains under consideration for future clinical development.
MannKind shares were down 7.5% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.